| Literature DB >> 32612953 |
Lili Xu1, Gumuyang Zhang1, Lun Zhao2, Li Mao2, Xiuli Li2, Weigang Yan3, Yu Xiao4, Jing Lei1, Hao Sun1, Zhengyu Jin1.
Abstract
Background: To develop a radiomics model based on multiparametric MRI (mpMRI) for preoperative prediction of extraprostatic extension (EPE) in patients with prostate cancer (PCa).Entities:
Keywords: extraprostatic extension; magnetic resonance imaging; neoplasm staging; prostate cancer; radiomics
Year: 2020 PMID: 32612953 PMCID: PMC7308458 DOI: 10.3389/fonc.2020.00940
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Radiomics workflow. The radiomics workflow includes tumor segmentation, feature extraction, radiomics model, clinical model, and radiomics nomogram construction and predictive performance validation.
Clinicopathological data of patients in this study.
| Age (year), mean ± SD | 64.83 ± 5.39 | 64.28 ± 5.32 | 65.54 ± 5.56 | 64.16 ± 5.85 | 65.79 ± 4.76 |
| t-PSA (ng/mL), mean ± SD | 13.00 ± 10.54 | 11.14 ± 6.34 | 19.16 ± 15.52 | 8.01 ± 3.36 | 10.58 ± 5.33 |
| f-PSA (ng/mL), mean ± SD | 1.59 ± 1.24 | 1.41 ± 9.44 | 2.19 ± 1.63 | 1.08 ± 0.70 | 1.40 ± 0.81 |
| F/T, mean ± SD | 0.13 ± 0.07 | 0.13 ± 0.06 | 0.13 ± 0.06 | 0.14 ± 0.06 | 0.16 ± 0.13 |
| 1–2 | 9 (7.8) | 4 (8.5) | 1 (2.9) | 3 (15.8) | 1 (7.1) |
| 3 | 4 (3.5) | 2 (4.3) | 1 (2.9) | 1 (5.3) | 0 (0.0) |
| 4 | 59 (51.3) | 30 (63.8) | 11 (31.4) | 12 (63.2) | 6 (42.9) |
| 5 | 43 (37.4) | 11 (23.4) | 22 (62.9) | 3 (15.8) | 7 (50.0) |
| 1 | 50 (43.5) | 22 (46.8) | 12 (34.3) | 13 (68.4) | 3 (21.4) |
| 2 | 29 (25.2) | 14 (29.8) | 6 (17.1) | 2 (10.5) | 7 (50.0) |
| 3 | 14 (12.2) | 6 (12.8) | 6 (17.1) | 1 (5.3) | 1 (7.1) |
| 4 | 9 (7.8) | 1 (2.1) | 6 (17.1) | 2 (10.5) | 0 (0.0) |
| 5 | 13 (11.3) | 4 (8.5) | 5 (14.3) | 1 (5.3) | 3 (21.4) |
EPE, extraprostatic extension; t-PSA, total prostate-specific antigen; f-PSA, free prostate-specific antigen; F/T, free/total PSA; PI-RADS, prostate imaging reporting and data system.
P < 0.05. Compared by Student's t-test, Mann–Whitney U-test, chi-squared test or Fisher's exact test when appropriate.
Figure 2The LASSO includes choosing the regular parameter lambda (λ) (A), determining the number of the feature (B). The optimal λ-value was 0.044237207 with transformed log (λ) of −3.5. Eight features were finally selected.
Figure 3The corresponding coefficients of the most predictive subset of features.
Diagnostic performance of different models.
| Clinical model | 0.730 | 0.622– | 67.1 | 85.7 | 53.19 | 0.658 | 0.450–0.866 | 69.7 | 71.4 | 68.4 |
| Radiomics model | 0.919 | 0.861– | 85.4 | 82.9 | 89.4 | 0.865 | 0.738– | 81.8 | 71.4 | 89.5 |
| Combined nomogram | 0.920 | 0.863– | 85.4 | 82.9 | 89.4 | 0.857 | 0.725– | 81.8 | 71.4 | 89.5 |
CI, confidence interval; AUC, area under the curve.
Figure 4The receiver operating characteristic curves of the radiomics model to differentiate EPE and non-EPE lesions in the training (A) and validation group (B). The calibration curve (C) of the radiomics model in the validation group showed good agreement between the predicted and actual probabilities. In the decision curve analysis (D), when Pt was 0.15–0.97, the net benefit of the model is better than that of the treat-all or treat-none schemes.